Compare Adecoagro SA (AGRO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Incyte Corporation — how do they compare? Adecoagro SA trades at $9.23 (market cap $1.36B), while Incyte Corporation trades at $120.7 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 18× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AGRO | INCY | |
|---|---|---|
Market Cap | $1.36B | $24.54B |
Sector | Technology | Health |
52-Week High | $15.25 | $129.93 |
52-Week Low | $7.13 | $81.61 |
Enterprise Value | $3.39B | $20.04B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.34, down 3.31% today, with a bearish technical signal from moving averages. The company reported mixed earnings, beating in Q3 2025 but missing in the last three quarters. Recent news highlights record adjusted EBITDA in Q2 2026 and an acquisition to expand operations. Valuation ratios like P/S of 0.71 and P/B of 0.77 suggest potential undervaluation, but low net income margins and negative recent EPS pose challenges.
The outlook is cautious; analyst consensus is mixed with 37.5% buy ratings. Upside potential exists from operational expansions and cost management, but risks include earnings volatility, high leverage from acquisitions, and commodity price exposure. Investors should weigh the low valuation against inconsistent profitability and macroeconomic headwinds.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
